GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » ROA %
中文

abrdn Life Sciences Investors (abrdn Life Sciences Investors) ROA %

: -5.48% (As of Sep. 2023)
View and export this data going back to . Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. abrdn Life Sciences Investors's annualized Net Income for the quarter that ended in Sep. 2023 was $-22.90 Mil. abrdn Life Sciences Investors's average Total Assets over the quarter that ended in Sep. 2023 was $417.64 Mil. Therefore, abrdn Life Sciences Investors's annualized ROA % for the quarter that ended in Sep. 2023 was -5.48%.

The historical rank and industry rank for abrdn Life Sciences Investors's ROA % or its related term are showing as below:

HQL' s ROA % Range Over the Past 10 Years
Min: -22.05   Med: 6.05   Max: 28.25
Current: 5.36

During the past 7 years, abrdn Life Sciences Investors's highest ROA % was 28.25%. The lowest was -22.05%. And the median was 6.05%.

HQL's ROA % is ranked better than
63.72% of 1717 companies
in the Asset Management industry
Industry Median: 2.6 vs HQL: 5.36

abrdn Life Sciences Investors ROA % Historical Data

The historical data trend for abrdn Life Sciences Investors's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

abrdn Life Sciences Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
ROA %
Get a 7-Day Free Trial -16.29 28.25 12.67 -22.05 5.47

abrdn Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.72 -31.06 -13.12 15.96 -5.48

Competitive Comparison

For the Asset Management subindustry, abrdn Life Sciences Investors's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


abrdn Life Sciences Investors ROA % Distribution

For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's ROA % distribution charts can be found below:

* The bar in red indicates where abrdn Life Sciences Investors's ROA % falls into.



abrdn Life Sciences Investors ROA % Calculation

abrdn Life Sciences Investors's annualized ROA % for the fiscal year that ended in Sep. 2023 is calculated as:

ROA %=Net Income (A: Sep. 2023 )/( (Total Assets (A: Sep. 2022 )+Total Assets (A: Sep. 2023 ))/ count )
=22.352/( (414.725+402.6)/ 2 )
=22.352/408.6625
=5.47 %

abrdn Life Sciences Investors's annualized ROA % for the quarter that ended in Sep. 2023 is calculated as:

ROA %=Net Income (Q: Sep. 2023 )/( (Total Assets (Q: Mar. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=-22.902/( (432.689+402.6)/ 2 )
=-22.902/417.6445
=-5.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Sep. 2023) net income data. ROA % is displayed in the 30-year financial page.


abrdn Life Sciences Investors  (NYSE:HQL) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=-22.902/417.6445
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-22.902 / -21.76)*(-21.76 / 417.6445)
=Net Margin %*Asset Turnover
=105.25 %*-0.0521
=-5.48 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2023) net income data. The Revenue data used here is two times the semi-annual (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


abrdn Life Sciences Investors ROA % Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description

Traded in Other Exchanges
N/A
Address
1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.
Executives
Todd Reit director C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Bill Maher director 600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino director C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
James Joseph O'connor other: Director of Adviser C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc. other: Adviser 1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar officer: VP and Chief Legal Officer 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols other: Director of Adviser 1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard officer: President ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy officer: Secretary and Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari officer: Treasurer and CFO 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson officer: Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina officer: Chief Compliance Officer & VP 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Stephen Bird director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10022

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Headlines

From GuruFocus

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 01-06-2021

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 02-15-2023

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 11-16-2020

Tekla Life Sciences Investors Paid Distribution

By Business Wire 06-30-2023

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-31-2020

Tekla Life Sciences Investors Declares Distribution

By Business Wire 08-15-2023

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-30-2022

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 03-31-2023

Tekla Life Sciences Investors Paid Distribution

By Business Wire 09-29-2023

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 06-30-2021